Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

IDS iSYS Launch

2 Mar 2009 07:00

RNS Number : 0777O
Immunodiagnostic Systems Hldgs PLC
02 March 2009
 



 

Immunodiagnostic Systems Holdings plc

IDS iSYS Launch

Following its announcement of the 28 January Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, announces the launch of its new fully-automated immunoanalyser, the IDS iSYS and at the same time the launch of its automated IDS iSYS Vitamin D assay.

IDS's automated version of its flagship product, 25 Hydroxy Vitamin D, a test to quantify vitamin D in patient serum or plasma, was CE marked on Friday 27 February and is now available for sale on its fully-automated immunoanalyser, the IDS iSYS.

Demand for vitamin D testing has been growing strongly in recent times due to the increasing awareness of the importance of 'adequacy' in vitamin D in reducing predisposition to numerous disease conditions, including common cancers (colon, breast and prostate) and autoimmune disease, as well as the long accepted role in building strong bones and teeth.

Additional diagnostic products in the field of Bone & Skeletal health and Growth Regulation will be launched during the year as the Company continues to develop and expand its range of automated products available on the IDS iSYS.

The Chief Executive Officer, Dr Roger Duggancommented: "The launch of the IDS iSYS represents a milestone in the Company's history, and follows a period of intense activity throughout the entire IDS Group. Automation of our highly specialized diagnostic products will take us into much larger and more prestigious clinical and corporate laboratories, accounts that were hitherto beyond our reach. The global IDS team has done a great job in bringing to fruition the launch of Vitamin D on the IDS iSYS following our acquisition of the technology in late 2007."

ENDS

Enquiries:

IDS

Tel: 0191 519 0660

Roger Duggan, CEO

Paul Hailes, Finance Director

www.idsplc.com

Parkgreen Communications Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@parkgreenmedia.com

Oriel Securities Ltd

Nominated Advisor and joint broker

Andrew Edwards

Tel: 020 7710 7600

Teathers

Joint broker

Shaun Dobson

Tel: 020 7426 9582

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDDLFLKLBXBBV

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.